Related Experiment Video
Updated: Nov 12, 2025
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD
Romain Cohen1,2, Heshan Liu1, Jack Fiskum1
1Department of Health Science Research, Mayo Clinic, Rochester, MN, USA.
First-line chemotherapy with anti-EGFR agents is ineffective for metastatic colorectal cancer (mCRC) patients with BRAFV600E mutations (BRAFmt). BRAFmt mCRC patients have significantly poorer overall survival compared to other mutation types.
Area of Science:
- Oncology
- Medical Genetics
- Clinical Trials
Background:
- First-line treatment for BRAFV600E-mutated metastatic colorectal cancer (BRAFmt mCRC) relies on subgroup analyses from randomized controlled trials (RCTs).
- Assessing the prognostic and predictive impact of BRAFmt on targeted therapy efficacy in first-line chemotherapy is crucial.
Purpose of the Study:
- To evaluate the impact of BRAFV600E mutation (BRAFmt) on patient outcomes in metastatic colorectal cancer (mCRC).
- To determine the efficacy of first-line chemotherapy combined with anti-epidermal growth factor receptor (anti-EGFR) agents in BRAFmt mCRC patients.
Main Methods:
- Pooled individual patient data from 10 first-line RCTs within the ARCAD database, including BRAF and KRAS mutation status.
- Progression-free survival and overall survival (OS) analyzed using Kaplan-Meier and Cox models.
- Comparison of outcomes between concurrently randomly assigned treatment groups.
Main Results:
- Included 6391 patients: 573 (9.0%) BRAFmt, 2059 (32.2%) KRASmt, and 3759 (58.8%) double wild-type.
- BRAFmt mCRC patients had significantly poorer OS than KRASmt (HRadj=1.46) and double wild-type (HRadj=2.14) groups.
- Anti-EGFR agents did not improve PFS or OS in BRAFmt mCRC patients when added to chemotherapy (PFS HRadj=0.96, OS HRadj=0.85).
Conclusions:
- First-line chemotherapy combined with anti-EGFR agents is ineffective for BRAFmt mCRC patients.
- BRAFmt is a significant negative prognostic factor for overall survival in mCRC.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
11:20Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018
